Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CRDF Stock Summary
Top 10 Correlated ETFs
CRDF
In the News
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5
You get what you pay for and that includes stocks under $5. Yeah, I might be starting off on a negative foot but here's the deal: most securities that are priced this low are that way for a reason.
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cardiff Oncology (CRDF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial.
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?
Does Cardiff Oncology (CRDF) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.20 per share a year ago.
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Mark Erlander - CEO Jamie Levine - CFO Conference Call Participants Mark Frahm - TD Cowen Joe Catanzaro - Piper Sandler Companies Andy Hsieh - William Blair & Company Operator Welcome to the Cardiff Oncology third-quarter 2023 financial results and corporate update conference call. [Operator Instructions].
Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Cardiff Oncology (CRDF) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CRDF Financial details
CRDF Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | |
Net income per share | -2.7 | -0.92 | -0.71 | -0.86 | -0.93 | |
Operating cash flow per share | -2.22 | -0.78 | -0.59 | -0.78 | -0.69 | |
Free cash flow per share | -2.23 | -0.79 | -0.6 | -0.8 | -0.7 | |
Cash per share | 1.71 | 6.27 | 3.61 | 2.41 | 1.67 | |
Book value per share | 1.22 | 6.14 | 3.6 | 2.44 | 1.56 | |
Tangible book value per share | 1.22 | 6.14 | 3.6 | 2.44 | 1.56 | |
Share holders equity per share | 1.22 | 6.14 | 3.6 | 2.44 | 1.56 | |
Interest debt per share | 0.29 | 0.04 | 0.08 | 0.1 | 0.05 | |
Market cap | 7.41M | 375.54M | 234.57M | 61.04M | 66.12M | |
Enterprise value | -1.06M | 245.42M | 225.75M | 47.41M | 46.62M | |
P/E ratio | -0.46 | -19.48 | -8.46 | -1.63 | -1.6 | |
Price to sales ratio | 30.24 | 1.03K | 653.4 | 158.13 | 135.5 | |
POCF ratio | -0.56 | -23.02 | -10.18 | -1.8 | -2.14 | |
PFCF ratio | -0.56 | -22.72 | -10.09 | -1.76 | -2.1 | |
P/B Ratio | 1.01 | 2.93 | 1.67 | 0.57 | 0.95 | |
PTB ratio | 1.01 | 2.93 | 1.67 | 0.57 | 0.95 | |
EV to sales | -4.33 | 670.57 | 628.82 | 122.82 | 95.52 | |
Enterprise value over EBITDA | 0.07 | -13.22 | -7.87 | -1.2 | -1.04 | |
EV to operating cash flow | 0.08 | -15.04 | -9.8 | -1.4 | -1.51 | |
EV to free cash flow | 0.08 | -14.85 | -9.71 | -1.37 | -1.48 | |
Earnings yield | -2.18 | -0.05 | -0.12 | -0.61 | -0.63 | |
Free cash flow yield | -1.8 | -0.04 | -0.1 | -0.57 | -0.48 | |
Debt to equity | 0.24 | 0.01 | 0.02 | 0.03 | 0.03 | |
Debt to assets | 0.13 | 0.01 | 0.02 | 0.02 | 0.03 | |
Net debt to EBITDA | 0.52 | 7.01 | 0.31 | 0.34 | 0.43 | |
Current ratio | 2.37 | 21.79 | 22.28 | 14.25 | 7.41 | |
Interest coverage | 0 | -12.56K | 0 | -25.24 | 0 | |
Income quality | 0.81 | 0.85 | 0.81 | 0.87 | 0.75 | |
Dividend Yield | 3.27 | 0.06 | 0 | 0.01 | 0 | |
Payout ratio | -1.5 | -1.26 | 0 | -0.01 | 0 | |
Sales general and administrative to revenue | 23.51 | 22.45 | 32.97 | 34.15 | 26.73 | |
Research and developement to revenue | 45.56 | 30.7 | 48.4 | 70.23 | 67.33 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 | |
Capex to revenue | -0.28 | -0.58 | -0.57 | -2.31 | -1.19 | |
Capex to depreciation | -0.14 | -0.45 | -0.45 | -3.78 | -1.46 | |
Stock based compensation to revenue | 3.61 | 4.82 | 9.01 | 11.03 | 9.24 | |
Graham number | 8.63 | 11.3 | 7.59 | 6.87 | 5.71 | |
ROIC | -1.52 | -0.15 | -0.19 | -0.35 | -0.62 | |
Return on tangible assets | -1.23 | -0.14 | -0.19 | -0.32 | -0.51 | |
Graham Net | 0.77 | 5.97 | 3.38 | 2.2 | 1.41 | |
Working capital | 6.57M | 127.24M | 139.57M | 103.48M | 66.97M | |
Tangible asset value | 7.31M | 128.16M | 140.42M | 106.34M | 69.74M | |
Net current asset value | 5.58M | 126.79M | 137M | 101.44M | 65.51M | |
Invested capital | 0.24 | 0.01 | 0.02 | 0.03 | 0.03 | |
Average receivables | 186K | 262.23K | 427.73K | 653K | 529.5K | |
Average payables | 660.5K | 1.01M | 1.4M | 1.7M | 1.96M | |
Average inventory | 0.5 | 0.5 | 0 | 0 | 0 | |
Days sales outstanding | 303.92 | 319.59 | 543.94 | 729.05 | 215.41 | |
Days payables outstanding | 21.45 | 44.38 | 1.05K | 3.57K | 1.8K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.2 | 1.14 | 0.67 | 0.5 | 1.69 | |
Payables turnover | 17.02 | 8.22 | 0.35 | 0.1 | 0.2 | |
Inventory turnover | 11.16M | 0 | 0 | 0 | 0 | |
ROE | -2.21 | -0.15 | -0.2 | -0.35 | -0.59 | |
Capex per share | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.18 | -0.23 | -0.25 | -0.22 | -0.21 | |
Operating cash flow per share | -0.22 | -0.19 | -0.16 | -0.18 | -0.16 | |
Free cash flow per share | -0.22 | -0.19 | -0.17 | -0.19 | -0.16 | |
Cash per share | 2.41 | 2.17 | 2 | 1.82 | 1.67 | |
Book value per share | 2.44 | 2.16 | 1.94 | 1.74 | 1.56 | |
Tangible book value per share | 2.44 | 2.16 | 1.94 | 1.74 | 1.56 | |
Share holders equity per share | 2.44 | 2.16 | 1.94 | 1.74 | 1.56 | |
Interest debt per share | 0.08 | 0.04 | 0.05 | 0.05 | 0.07 | |
Market cap | 61.04M | 73.72M | 65.6M | 62.1M | 66.12M | |
Enterprise value | 47.41M | 61.28M | 48.66M | 49.16M | 46.62M | |
P/E ratio | -1.91 | -1.77 | -1.47 | -1.6 | -1.77 | |
Price to sales ratio | 476.88 | 888.16 | 607.38 | 440.43 | 423.86 | |
POCF ratio | -6.5 | -8.51 | -9.2 | -7.8 | -9.26 | |
PFCF ratio | -6.45 | -8.51 | -8.88 | -7.51 | -9.25 | |
P/B Ratio | 0.57 | 0.76 | 0.76 | 0.8 | 0.95 | |
PTB ratio | 0.57 | 0.76 | 0.76 | 0.8 | 0.95 | |
EV to sales | 370.38 | 738.28 | 450.6 | 348.67 | 298.82 | |
Enterprise value over EBITDA | -5.09 | -5.12 | -4.02 | -4.59 | -4.56 | |
EV to operating cash flow | -5.05 | -7.08 | -6.82 | -6.18 | -6.53 | |
EV to free cash flow | -5.01 | -7.07 | -6.59 | -5.94 | -6.52 | |
Earnings yield | -0.13 | -0.14 | -0.17 | -0.16 | -0.14 | |
Free cash flow yield | -0.16 | -0.12 | -0.11 | -0.13 | -0.11 | |
Debt to equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Debt to assets | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
Net debt to EBITDA | 1.46 | 1.04 | 1.4 | 1.21 | 1.91 | |
Current ratio | 14.25 | 12.49 | 10.16 | 9.3 | 7.41 | |
Interest coverage | -12.69 | 14.54 | 0 | 0 | -12.46 | |
Income quality | 1.08 | 0.77 | 0.64 | 0.82 | 0.76 | |
Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.05 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 24.05 | 37.14 | 39.78 | 20.84 | 17.47 | |
Research and developement to revenue | 50.33 | 109.06 | 74.26 | 56.89 | 49.76 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0.04 | 0.04 | 0 | |
Capex to revenue | -0.59 | -0.1 | -2.32 | -2.23 | -0.05 | |
Capex to depreciation | -0.87 | -0.09 | -2.56 | -2.94 | -0.08 | |
Stock based compensation to revenue | 7.91 | 12.82 | 14.64 | 6.77 | 5.83 | |
Graham number | 3.17 | 3.36 | 3.3 | 2.92 | 2.71 | |
ROIC | -0.08 | -0.11 | -0.12 | -0.12 | -0.19 | |
Return on tangible assets | -0.07 | -0.1 | -0.11 | -0.11 | -0.11 | |
Graham Net | 2.2 | 1.96 | 1.76 | 1.59 | 1.41 | |
Working capital | 103.48M | 93.61M | 83.61M | 74.89M | 66.97M | |
Tangible asset value | 106.34M | 96.5M | 86.58M | 77.83M | 69.74M | |
Net current asset value | 101.44M | 91.71M | 81.86M | 73.28M | 65.51M | |
Invested capital | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
Average receivables | 710.5K | 723.5K | 418.5K | 179.5K | 243K | |
Average payables | 1.69M | 2.44M | 2.93M | 2.56M | 2.07M | |
Average inventory | 0.5 | 0 | 0.5 | 0.5 | 0 | |
Days sales outstanding | 542.11 | 733.01 | 134.17 | 126.38 | 166.15 | |
Days payables outstanding | 3.52K | 2.91K | 2.7K | 1.83K | 1.72K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.17 | 0.12 | 0.67 | 0.71 | 0.54 | |
Payables turnover | 0.03 | 0.03 | 0.03 | 0.05 | 0.05 | |
Inventory turnover | 0 | 0 | 98K | 0 | 0 | |
ROE | -0.08 | -0.11 | -0.13 | -0.13 | -0.13 | |
Capex per share | 0 | 0 | -0.01 | -0.01 | 0 |
CRDF Frequently Asked Questions
What is Cardiff Oncology, Inc. stock symbol ?
Cardiff Oncology, Inc. is a US stock , located in San diego of Ca and trading under the symbol CRDF
What is Cardiff Oncology, Inc. stock quote today ?
Cardiff Oncology, Inc. stock price is $5.34 today.
Is Cardiff Oncology, Inc. stock public?
Yes, Cardiff Oncology, Inc. is a publicly traded company.